Idiopathic pulmonary fibrosis is the most common idiopathic interstitial pneumonia. Prognosis is poor with a median survival <3 years. Pirfenidone is one of two US Food and Drug Administration-approved medications that slow disease progression. We describe the development of lymphadenopathy or a sarcoid-like reaction following initiation of pirfenidone, a complication not previously reported.
Keywords: drug toxicity; idiopathic pulmonary fibrosis; lung transplant; pirfenidone (Esbrit); sarcoid-like reaction.
Published by Elsevier Inc.